Aclaris's Q2 2026 net loss widened 39.4% to $21.5M as R&D jumped 57.8% on ATI-052 and ATI-9494, funded by share sales that left $170.6M in cash plus $40.2M raised in July ahead of H2 2026 trial read-outs.